Aquestive Therapeutics (AQST) Earnings Date & Reports

Key Takeaways

• Aquestive Therapeutics reported third-quarter 2026 revenue of $7.5 million, down 41.5% year over year and well below the consensus estimate of roughly $11.0 million.
• GAAP net loss per share was $0.18, missing the analyst consensus of a $0.12 loss per share.
• Non-GAAP adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss widened to $12.2 million from $8.6 million a year earlier.
• The company resubmitted its Anaphylm New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the quarter, a key regulatory milestone.
• Aquestive reaffirmed its full-year 2026 guidance of $46 million to $50 million in revenue and a non-GAAP adjusted EBITDA loss of $30 million to $35 million.
• You can find more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see how AI-driven trading tools are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

Aquestive Therapeutics is a specialty biopharmaceutical company built around its proprietary oral-film delivery technology, with investors focused primarily on the progress of its lead pipeline candidate, Anaphylm, a sublingual film being developed for severe allergic reactions including anaphylaxis. The third quarter carried outsized weight because management had guided toward resubmitting the Anaphylm NDA during the period following an earlier Complete Response Letter from the FDA. Quarterly revenue remains secondary to the regulatory story, but a sharp year-over-year decline and a sizeable miss versus consensus still matter, because they signal the commercial and royalty mix that will fund the company's launch ambitions and cash runway ahead of a potential approval.

Reported Results

For the third quarter ended September 30, 2026, Aquestive reported total revenue of $7.5 million, a 41.5% decline from $12.8 million in the prior-year period and below the consensus estimate of approximately $11.0 million. The net loss per share was $0.18 on a GAAP (Generally Accepted Accounting Principles) basis, compared with a loss of $0.14 a year ago and versus the consensus expectation of a $0.12 loss. Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million in the same quarter last year. Cash and cash equivalents stood at $90.3 million at quarter-end, down from $121.2 million at the end of 2025.

Operationally, the company resubmitted the Anaphylm NDA in the third quarter, a milestone that management has described as central to its strategy. In October, after the quarter closed, Aquestive completed an out-licensing transaction for Libervant, providing $10 million in upfront, non-dilutive capital plus up to $47.5 million in potential regulatory and sales-based milestones and mid-teens royalties on net sales.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following specialty pharmaceutical names like Aquestive Therapeutics, the AI Screener offers a structured way to surface comparable setups and monitor shifting market conditions across the healthcare sector.

Market Reaction and Investor Sentiment

Shares of Aquestive Therapeutics traded lower in after-hours activity following the release, with the stock falling roughly 2.6% to around $3.78 after closing at $3.88. The stock has declined approximately 39% to 42% since the start of 2026, underperforming the broader market by a wide margin. Investor sentiment remains anchored to the Anaphylm regulatory timeline rather than near-term revenue, but the revenue miss and widening adjusted EBITDA loss reinforced concerns about the company's cash position and the time required to reach a potential commercial launch. The October Libervant licensing deal and the completed NDA resubmission are likely to be read as positive offsets, though the market's immediate reaction suggests caution around execution and capital requirements.

Forward Outlook and Key Factors to Monitor

The most important catalyst ahead is the FDA's review of the resubmitted Anaphylm NDA. Management has indicated that the base case assumes a six-month review clock, though it has also suggested the limited scope of the resubmission package could support a faster timeline. The timing and outcome of that review will define the company's commercial trajectory.

Investors should also watch how the October Libervant out-licensing transaction contributes to future quarters. The $10 million upfront payment and the potential for additional milestone and royalty income offer non-dilutive capital that could ease funding pressure as the company prepares for a potential Anaphylm launch.

Cash management remains a key theme. With $90.3 million in cash at quarter-end and a full-year adjusted EBITDA loss still guided to between $30 million and $35 million, the path to launch will depend on access to committed funding tied to regulatory milestones. Finally, coverage and reimbursement efforts for Anaphylm, if approved, will be an important watch item, as the company has acknowledged that payer access and physician adoption will take time to establish in the epinephrine market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations